FIELD: medicine; immunology.
SUBSTANCE: group of inventions relates to the field of medicine, namely to immunology; it can be used for increasing immune response of T-helper 1 (Th1) of a subject to a vaccine against bacterial infection. A method is proposed, which includes injecting the subject with one or more doses of interleukin-4 receptor (hereinafter – IL-4R) antagonist before, after and/or simultaneously with the vaccine, wherein IL-4R antagonist is an antibody or its antigen-binding fragment, which binds IL-4Rα. The group of inventions also relates to a combination containing the vaccine against bacterial infection and adjuvant, which is IL-4R antagonist, which is an antibody or its antigen-binding fragment, which binds IL-4Rα.
EFFECT: group of inventions provides for an increase in the vaccine efficiency.
17 cl, 10 dwg, 9 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR PREVENTING OR TREATING ALLERGIES BY INTRODUCING AN IL-4R ANTAGONIST | 2017 |
|
RU2777328C2 |
| METHODS FOR TREATMENT OF ACTIVE EOSINOPHILIC ESOPHAGITIS | 2018 |
|
RU2776651C2 |
| TREATMENT AND INHIBITION OF INFLAMMATORY LUNG DISEASES IN PATIENTS WITH RISK ALLELES IN GENES ENCODING IL33 AND IL1RL1 | 2018 |
|
RU2776241C2 |
| METHODS OF TREATING CHRONIC SINUSITIS WITH NASAL POLYPS BY ADMINISTERING IL-4R ANTAGONIST | 2015 |
|
RU2734490C2 |
| METHODS OF TREATMENT OR PREVENTION OF ASTHMA THROUGH ADMINISTRATION OF IL-4R ANTAGONIST | 2013 |
|
RU2801531C2 |
| METHOD OF TREATMENT OF ATOPIC DERMATITIS THROUGH INTRODUCTION OF IL-4R INHIBITOR | 2019 |
|
RU2801204C2 |
| ANTIBODY TO IL-4Rα AND APPLICATION THEREOF | 2018 |
|
RU2758092C1 |
| FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN CANCER TREATMENT | 2016 |
|
RU2745707C2 |
| AVELUMAB DOSING MODE FOR TREATMENT OF MALIGNANT NEOPLASM | 2017 |
|
RU2777363C2 |
| ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE | 2019 |
|
RU2795457C2 |
